Prednisolone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Prednisolone: From Autoimmune and Inflammatory Disease to Alopecia Areata
One-Sentence Summary
Prednisolone is a glucocorticoid originally used for autoimmune and inflammatory conditions (such as Crohn disease, inflammatory bowel disease and adrenocortical insufficiency) and for certain leukemias. The TxGNN model predicts it may be effective for Alopecia Areata, with 0 registered clinical trials but 20 publications (including a placebo-controlled RCT, a network meta-analysis and several reviews) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, Crohn disease and inflammatory bowel disease, adrenocortical insufficiency, acute lymphoblastic leukemia, and others (taken from the knowledge-graph indication list; no approved-indication text is available from the US licenses) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 13 licenses in total (all cancelled) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, prednisolone is a glucocorticoid that suppresses T-cell activation and pro-inflammatory cytokine production.
Alopecia areata is a T-cell mediated autoimmune attack on the hair follicle, with collapse of the follicle’s immune privilege. Prednisolone is already used in other autoimmune diseases, so its immunosuppressive action addresses the same type of mechanism. One study also reported that oral pulse steroids alter serum and tissue TNF-α levels in alopecia areata, a possible mechanism of action.
Support comes from a placebo-controlled study of oral pulse prednisolone and from multiple systematic reviews. Guardrails apply: relapse after discontinuation is common, and systemic corticosteroid adverse effects (HPA axis suppression, metabolic and bone effects, growth effects in children) limit long-term use. Newer options such as JAK inhibitors are also available.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15692475 | 2005 | RCT | J Am Acad Dermatol | Placebo-controlled trial of oral pulse prednisolone in alopecia areata; earlier studies had not been randomized or placebo-controlled |
| 37870096 | 2023 | Network meta-analysis | Cochrane Database Syst Rev | Compares treatments for alopecia areata, including immunosuppressants, hair growth stimulants and contact immunotherapy |
| 30191561 | 2019 | Systematic review | Australas J Dermatol | Evaluates the evidence for systemic treatments, which varies in strength |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse therapy |
| 36461625 | 2023 | Review | Pediatr Dermatol | Reviews dosing regimens and side effects of pulse corticosteroids in children; regimens are not well established |
| 21572877 | 2009 | Clinical study | Dermato-endocrinology | Medium-dose prednisolone pulse therapy; effective in early stages, but significant side effects may lead to discontinuation |
| 28140540 | 2017 | Cohort/clinical study | J Dtsch Dermatol Ges | Sequential high- then low-dose systemic corticosteroids for severe childhood alopecia areata |
| 26179196 | 2015 | Long-term follow-up | Dermatol Ther | Oral pulse plus topical corticosteroids in 65 children with severe disease, median follow-up 96 months |
| 30294905 | 2019 | Mechanistic study | J Cosmet Dermatol | Changes in TNF-α levels as a possible mechanism of oral pulse steroids |
| 32779249 | 2020 | Retrospective study | J Eur Acad Dermatol Venereol | Continuation rates of steroid-sparing agents (azathioprine, methotrexate, cyclosporine) in 138 patients with chronic disease |
US Market Information
All 13 US licenses in the data are cancelled; no valid license is currently listed. Approved-indication text is not available. Five representative entries:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021959 | Orapred | Tablet, orally disintegrating | Not available |
| NDA017011 | Prednisolone Acetate | Suspension/drops | Not available |
| NDA017469 | Prednisolone Acetate | Suspension/drops | Not available |
| ANDA218083 | Prednisolone | Tablet | Not available |
| ANDA075988 | Prednisolone Sodium Phosphate | Solution | Not available |
Note that some listed licenses are for methylprednisolone products (e.g., SOLU-MEDROL), which are a related but different drug.
Safety Considerations
- Contraindications (from knowledge-graph drug-disease edges, not label text): hypertension, epilepsy, hyperglycemia, congestive heart failure, herpes simplex virus keratitis, measles, inherited porphyria, urea-cycle disorders (e.g., carbamoyl phosphate synthetase I deficiency, citrullinemia, hyperargininemia), and pituitary hormone deficiency conditions (hypopituitarism, growth hormone deficiency, hypogonadotropic hypogonadism, Kallmann syndrome).
- Drug Interactions: 100 interactions were found. Notable examples:
- Major: adalimumab
- Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alemtuzumab, aliskiren, and tetanus toxoid vaccine
- Minor: formoterol, salbutamol
- Class effects noted in the literature: HPA suppression, metabolic and bone effects, and growth effects in children with systemic use.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Alopecia areata is the only predicted indication with direct supporting evidence: a placebo-controlled RCT of oral pulse prednisolone plus several systematic reviews, giving evidence level L2. No registered trials were found, relapse after stopping is common, and systemic steroid toxicity limits long-term use.
To proceed, the following is needed:
- Registered or new controlled trials of prednisolone in alopecia areata
- Comparison with JAK inhibitors and other current options
- Package insert warnings and contraindications (FDA label review)
- Detailed mechanism of action data (MOA)
- A safety monitoring and relapse-management plan, especially for children
Other predicted indications (for reference):
- Hold: alopecia mucinosa (only a cyclosporine case report; needs exclusion of cutaneous T-cell lymphoma), folliculitis decalvans (only a triple-therapy case, so the prednisolone contribution cannot be isolated), and alopecia antibody deficiency (indirect evidence only).
- Hold, prediction only: telogen effluvium, hereditary hypotrichosis with recurrent skin vesicles, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, atrichia with papular lesions, and prolapse of lacrimal gland. No supporting studies or plausible mechanism were identified.
- Research Question: idiopathic steroid-sensitive nephrotic syndrome (L3). Prednisolone is already first-line standard care here, so this is likely not true repurposing; the retrieved literature mostly concerns steroid-resistant disease. It should be reconciled with the original indication list.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.